Abstract Various ABC transporters can translocate lipid molecules from the cytoplasmic into the exoplasmic leaflet of the plasma membrane bilayer. Two of these, MDR1 P-glycoprotein (Pgp) and MRP1, are multidrug transporters responsible for the resistance of various cancers against chemotherapy. We wanted to study whether MRP2, an ABC transporter of the bile canalicular membrane with a substrate specificity very similar to that of MRP1, is capable of translocating lipids. The translocation of short-chain lipids across the apical membrane of MDCK cells transfected with MRP2 was significantly higher than that in untransfected controls. However, the characteristics of the lipid translocation were similar to substrate transport by MDR1 and not MRP2: transport was strongly inhibited by classic MDR1 Pgp inhibitors, was independent of cellular glutathione, and was insensitive to a drug known to inhibit MRP2 activity. When tested by immunoblot, the MRP2-transfected cells expressed high levels of MRP2 but also of endogenous Mdr1. The expression of Mdr1 was unstable during maintenance of the cell line and correlated with the rate of lipid translocation across the apical membrane. We conclude that the observed increase in lipid transport in the MDCK cells transfected with MRP2 is the consequence of the upregulation of the expression of endogenous Mdr1 and that careful characterization of endogenous Mdr1 expression is needed in studies aimed to identify substrates of plasma membrane transporters.
Introduction
It has been suggested that the energy needed to drive endocytosis is provided by the aminophospholipid translocator (Farge et al. 1999) . Under consumption of ATP this protein moves (aminophospho)lipid molecules from the outer leaflet of the plasma membrane bilayer into the cytosolic leaflet, and the resulting increase in the lateral pressure of the inner vs the outer leaflet would generate the force needed for inward budding of vesicles. Over the last 5 years, various ATP-binding cassette (ABC) transporters have been identified as lipid flippases in the opposite direction (see Borst et al. 2000; Raggers et al. 2000) . Two of these are the human multidrug resistance protein MRP1 and the MDR1 P-glycoprotein (Pgp) that actively transport a wide range of compounds across membranes out of the cytosol. MRP1 and MDR1 Pgp are highly expressed in a number of cancer cells, where they oppose chemotherapy by pumping drugs out of the cells (Gottesman and Pastan 1993) . The drugs transported by MRP1 and MDR1 Pgp have in common that they have an amphipathic character. Over the past decade, it has been demonstrated that MRP1 and MDR1 Pgp, and a number of other ABC transporters, translocate analogs of membrane lipids across the bilayer. A fluorescent analog of the glycosphingolipid glucosylceramide (C 6 -NBD-GlcCer) is a substrate for both proteins. However, C 6 -NBD-phosphatidylcholine (C 6 -NBD-PC) was exclusively transported by MDR1 Pgp. Whereas lipid transport by MRP1 was sensitive to MRP1 inhibitors such as indomethacin and depended on glutathione (Raggers et al. 1999) , this was not the case for lipid translocation by MDR1 Pgp. The latter transport was selectively sensitive to MDR1 inhibitors such as PSC833 and verapamil (van Helvoort et al. 1996; Bosch et al. 1997) .
MRP2 belongs to the ABCC-gene family (ABCC2) and shows 49% amino acid sequence identity with MRP1 (ABCC1; Keppler et al. 1997) . While MRP1 is detected in the plasma membrane of many cell types, including erythrocytes, and is limited to the basolateral membrane of polarized cells like other types of transporter proteins (Sugawara-Yokoo et al. 2000) , MRP2 has been localized to apical domains, and particularly to the hepatocyte canalicular membrane like other transporter proteins in other cell types (Haila et al. 2000) . MRP1 and MRP2 display highly overlapping substrate specificities, including physiologically important glutathione Sconjugates such as leukotriene C4, bilirubin glucuronides, and glutathione disulfide (Keppler et al. 1997) . They have a common, but not identical, sensitivity to indomethacin and glutathione depletion (Bakos et al. 2000; Evers et al. 2000) . MRP2 is deficient in Dubin-Johnson syndrome (Paulusma et al. 1996) , which is therefore associated with an inherited deficiency in the secretion of amphiphilic anionic conjugates into the bile of these patients.
In order to study whether MRP2, like MRP1, is capable of moving short-chain lipids across the plasma membrane, we made use of Madin-Darby canine kidney (MDCK) strain II cells transfected with human MRP2 cDNA, in which MRP2 has been shown to be located in the apical membrane (Evers et al. 1998 . The cells were allowed to synthesize C 6 -NBD-lipids from exogenously added precursors, and transport to the outer leaflet of the plasma membrane was studied as before (Fig. 1; van Helvoort et al. 1996; Raggers et al. 1999) . Transfection of MDCK II cells with human MRP2 enhanced transport of C 6 -NBD-GlcCer and C 6 -NBD-PC across the apical membrane of these cells. However, the increase in transport appears to be the consequence of the upregulation of endogenous Mdr1 expression and is independent of MRP2, as shown by an analysis of the expression of both proteins and of the drug sensitivity of the observed transport.
Materials and methods

Materials
D,L-Buthionine [S,R]-sulfoximine (BSO), bovine serum albumin fraction V (BSA), and glutathione ethyl ester were purchased from Sigma (St. Louis, Mo., USA). Indomethacin was from ICN (Aurora, Ohio, USA), and PSC833 was a kind gift of Novartis (Basel, Switzerland). C 6 -NBD-ceramide was from Molecular Probes (Eugene, Ore., USA). C 6 -NBD-phosphatidic acid (C 6 -NBD-PA) was from Avanti Polar Lipids (Alabaster, Ala., USA). Organic solvents and silica TLC plates were from Merck (Darmstadt, Germany) and cell culture media from Gibco (Paisley, UK).
Cell culture MDCK II cells transfected with MRP1 (Evers et al. 1997) , with MRP2 (Evers et al. 1998) , clone MRP227, and with MDR1 Pgp were a kind gift of Dr. S. Smith. Cells were cultured (mycoplasma-free) in MEM/10 mM HEPES, as in Pomorski et al. (1999) , but supplemented with 5% FCS. For experiments 2×10 6 cells on 4.7 cm 2 Transwells (Costar, Cambridge, Mass., USA) were grown as monolayers for 3-5 days.
Transport incubations
The precursors C 6 -NBD-ceramide and C 6 -NBD-PA were added to MDCK cell monolayers and transport of C 6 -NBD-GlcCer and C 6 -NBD-PC, respectively, to the apical and basolateral surface were measured after 3 h at 15°C as before, using BSA depletion from the surface, lipid extraction, two-dimensional TLC, and fluorescence quantitation (van Helvoort et al. 1996; Raggers et al. 1999 ). Inhibitors were added 10 min before the start of the transport incubation. Glutathione depletion was carried out as before (Raggers et al. 1999 ).
Western blots
The levels of MDR1 Pgp and MRP2 were determined in total cell lysates. For this, 80 µg protein was size-separated on a 10% (w/v) polyacrylamide gel containing 0.1% SDS (w/v). After electroblotting to nitrocellulose, MDR1 Pgp was visualized by using monoclonal antibody JSB1 or C219 [kind gifts of Dr. R. Schepers (Free University, Amsterdam)] and MRP2 was visualized by staining with monoclonal antibody M2-III-6 (a kind gift from Dr. R. Oude Elferink, University of Amsterdam). Bands were visualized by the enhanced chemiluminescence procedure (Amersham) using Kodak BioMax MS X-ray films.
Results and discussion
Translocation of C 6 -NBD-GlcCer by MDCK-MRP2 cells C 6 -NBD-GlcCer has been found to be a substrate for translocation by both MDR1 Pgp (van Helvoort et al. 1996) and MRP1 (Raggers et al. 1999) . In these studies, A short-chain lipid precursor, C 6 -NBD-ceramide or C 6 -NBDphosphatidic acid, is added to a confluent monolayer of MadinDarby canine kidney (MDCK) cells on a permeable support. The cells had been transfected with either MDR1 P-glycoprotein (Pgp), MRP1, or MRP2. The cells are incubated for 3 h at 15°C in the presence of serum albumin (BSA) both in the apical medium in the filter cup and in the basolateral medium underneath the filter. Any newly synthesized short-chain fluorescent lipid product that reaches the cell surface is trapped by the BSA. Finally, the fluorescent lipids in media and cells are quantitatively analyzed. GlcCer Glucosylceramide, SM sphingomyelin a confluent monolayer of epithelial LLC PK1 cells was incubated with C 6 -NBD-ceramide for 3 h at 15°C. Because of its short acyl chain C 6 -NBD-ceramide diffuses across aqueous phases and because it has no polar headgroup it rapidly crosses membranes. Thus, C 6 -NBDceramide reaches the Golgi where it is converted to C 6 -NBD-GlcCer on the cytosolic surface and to C 6 -NBDsphingomyelin (SM) in the lumen. Consequently, C 6 -NBD-GlcCer can equilibrate with the cytosolic surface of the plasma membrane (Jeckel et al. 1992; van Helvoort et al. 1996 ). When C 6 -NBD-GlcCer is translocated across the plasma membrane to the exoplasmic leaflet, it is extracted by BSA in the apical or basolateral medium which binds this short-chain lipid and acts as a sink. C 6 -NBD-SM is sequestered in the lumen of the Golgi and has no access to the cytosolic surface of the plasma membrane. Arrival of C 6 -NBD-GlcCer on the surface by exchange through the cytosol and translocation is discriminated from delivery to the plasma membrane via vesicular transport by the incubation conditions. At 15°C the traffic of membrane vesicles, but not aqueous transfer and translocation, is blocked.
In order to test whether MRP2 is capable of translocating short-chain lipids across the plasma membrane, we first tested C 6 -NBD-GlcCer as a substrate for translocation in MDCK II cells stably transfected with MRP2. MDCK-MDR1 and MDCK-MRP1 were included as positive controls and untransfected MDCK II cells as a negative control. After the transport assay, more of the newly synthesized C 6 -NBD-GlcCer was recovered in the apical medium of MDCK-MDR1 cells and in the basolateral medium of MDCK-MRP1 cells than in the media of MDCK II control cells (Table 1) which is in accordance with the published data for transfected LLC PK1 cells. In addition, more C 6 -NBD-GlcCer was found in the apical medium of MDCK-MRP2 cells than in the control, whereas the percentage found in the basal medium was similar. This suggests that MRP2 translocated C 6 -NBDGlcCer across the apical membrane, which would fit the localization of MRP2 to the apical membrane of the MDCK-MRP2 cells (Evers et al. 1998 ).
Substrate specificity in MDCK-MRP2 cells C 6 -NBD-PC and C 6 -NBD-phosphatidylethanolamine (C 6 -NBD-PE) have been found to be substrates for translocation by MDR1 Pgp (van Helvoort et al. 1996) , but not MRP1 (Raggers et al. 1999) . When transport of C 6 -NBD-PC and C 6 -NBD-PE was measured in MDCK-MRP2, clearly, both lipids were translocated across the apical surface of these cells (Table 1) . This was unexpected since the substrate specificity of MRP1 and MRP2 is very similar. The activity in MDCK-MRP2 cells resembled that of MDCK-MDR1.
Inhibitor sensitivity in MDCK-MRP2 cells
The difference in substrate specificity between MDR1 Pgp and MRP1 is also illustrated by their different sensitivities to inhibitors. Whereas MDR1 Pgp is typically inhibited by verapamil, cyclosporin, and PSC833, MRP1 is insensitive to these drugs but is sensitive to indomethacin. Verapamil, cyclosporin, and PSC833 inhibited transport of C 6 -NBD-GlcCer toward the apical surface of MDCK-MRP2 cells by 87% (n=2), by 94% (n=4), and 98% (n=4), respectively. Transport toward the basolateral surface was inhibited by 70-90% by the respective inhibitors. This most likely reflects the fact that the small increase of basolateral transport as compared to the control is due to missorting of a small fraction of the apical translocator (cf. van Helvoort et al. 1996) . Indomethacin had no effect on C 6 -NBD-GlcCer transport toward the apical medium (103% of control MDCK-MRP2) and inhibited basolateral transport by 30% suggesting that basolateral transport is partially due to endogenous Mrp1. Overall, the inhibition profile of lipid translocation in MDCK-MRP2 cells resembled that of MDR1 Pgp not MRP1.
Glutathione is a substrate for both MRP1 and MRP2 and free glutathione greatly stimulates transport of substrates that are not covalently attached to glutathione. Glutathione depletion reduced lipid translocation by Table 1 Transport of C 6 -NBD-lipids to the surface of Madin-Darby canine kidney (MDCK) cells at 15°C. Cells were incubated with 5 µM C 6 -NBD-ceramide, as a precursor for glucosylceramide (GlcCer) and sphingomyelin (SM), or with 25 µM C 6 -NBD-phosphatidic acid, as a precursor for phosphatidylcholine (PC) and phosphatidylethanolamine (PE), during 3 h at 15°C, after which the cell surface was washed free of NBD-lipids. The lipids in the combined media and washes were analyzed and quantified. Transport is expressed as the percentage of each fluorescent lipid recovered in apical or basolateral medium. In all cell lines, roughly 5% of the newly synthesized C 6 -NBD-SM was recovered in the apical medium, and dependent on the cell line 15-30% was recovered in the basolateral medium. The latter and the PC in the basolateral medium are the result of synthesis on the basolateral cell surface (van Helvoort et al. 1994) . Numbers are followed by the standard deviation, and the number of measurements is in parentheses. [ND C 6 -NBD-PC and C 6 -NBD-PE are not translocated by MRP1 (Raggers et al. 1999 ) and this was not further studied here]
25±10 (14) 6±4 (14) 15±2 (4) 41±5 (4) 23±13 (4) 6±2 (4) MDCK-MDR1 28±10 (9) 5±2 (9) 15±3 (4) 43±12 (4) 28±18 (4) 5±3 (4) MRP1 but not by MDR1 Pgp (Raggers et al. 1999) . Basolateral transport of C 6 -NBD-GlcCer in MDCK-MRP1 cells was only 13% in 3 h at 15°C after glutathione depletion by 24 h preincubation with 25 µM BSO, as compared to 29% in the presence of BSO plus glutathione ethyl ester (which restores the glutathione level; n=2). In contrast, BSO treatment had essentially no effect on apical transport in MDCK-MRP2 (93% of the control), while addition of glutathione ethyl ester lowered this number further to 77% instead of correcting the effect of BSO. Lipid translocation in MDCK-MRP2 appeared independent of glutathione, which further argues against a role for MRP2 in the translocation event.
Lipid translocation in MDCK II cells is unstable during cell culture
The MDCK-MRP2 cells displayed a stable level of C 6 -NBD-GlcCer translocation, 25% during 3 h at 15°C, for 3 months, when over a period of several weeks the translocation went down to 9±1% (n=6). In addition, we observed at a different point in time that the C 6 -NBD-GlcCer translocation in the control MDCK II cells rose from a level of 3% to a new stable level of 10±1% (n=4) over a period of weeks. Finally, we measured that the C 6 -NBD-GlcCer translocation activity depended on the number of days in culture. After 9 days in culture, C 6 -NBD-GlcCer translocation over the apical surface of MDCK II cells and MDCK-MRP2 cells was 2 times higher than after 2 days in culture (n=3). In one experiment, the C 6 -NBD-GlcCer translocation in control MDCK II cells rose to 22% (n=2, range 1%) in 3 h at 15°C. Because these phenomena were observed in MDCK II, MDCK-MRP1, and in MDCK-MRP2 cells, we concluded that the variable expression of one common translocator might be the cause of the variation in translocation activity.
Endogenous Mdr1 expression is upregulated in MRP2-transfected MDCK II cells
In order to establish whether possibly endogenous Mdr1 was upregulated in the MDCK-MRP2 cells, the cellular proteins were separated by SDS-PAGE, transferred to nitrocellulose, and blotted with the anti-MRP2 monoclonal antibody M2-III-6 and with the anti-MDR1 Pgp antibody. We included the MDCK-MRP2 line that had a strongly reduced ability to translocate C 6 -NBD-GlcCer ("inactive" MDCK-MRP2). As shown in Fig. 2 , both MDCK-MRP2 lines abundantly express MRP2, whereas the protein was absent from MDCK II control cells and from MDCK-MDR1. Since the MDCK-MRP2 cells in lane 2 had lost the capability to translocate C 6 -NBD-GlcCer, the presence of MRP2 did not correlate with translocation activity. In contrast, the anti-MDR1 antibody recognized human MDR1 Pgp in the MDCK-MDR1 cells, but also yielded a marked signal in MDCK II and in the two MDCK-MRP2 lines. From the fact that the "active" MDCK-MRP2 contained far higher levels of Mdr1 signal than the "inactive" MDCK-MRP2 cells but showed no difference in MRP2, we conclude that the endogenous Mdr1 Pgp was responsible for the high capacity to translocate C 6 -NBD-GlcCer. The upregulated expression of endogenous Mdr1 Pgp also explains that C 6 -NBD-PC and C 6 -NBD-PE were translocated, that translocation was sensitive to MDR1 inhibitors but not to an MRP1 inhibitor, and that translocation was insensitive to glutathione depletion.
Summarizing remarks
One accepted approach in the field of transporter function is the expression or overexpression of a specific transport protein in a cell line with a low background of the endogenous protein.
The assumption in such an approach is that the expression of the endogenous protein remains low during the transfection procedure and that the activity of the protein under study can be characterized by comparing transport in the transfected cells to that in mock-transfected controls. This approach has been validated by our characterization of the lipid substrate specificity of the ABC transporters MDR3 Pgp, MDR1 Pgp, and MRP1 using pig kidney-derived LLC PK1 cells as host cells (van Helvoort et al. 1996; Raggers et al. 1999) . However, in the present study we report upregulation of the expression of Mdr1 Pgp in an MDCK II cell line that had been transfected with MRP2. Without proper controls, we might have assigned proper- 
